SmartTRAK experts across orthopedics, sports medicine, spine and enabling technology attended this year’s 2024 Canaccord Genuity Musculoskeletal and American Academy of Orthopedic Surgeons (AAOS) annual conferences. Held from February 12-15 in San Francisco, CA, these gatherings brought together the top minds in the industry. In this post, we share some key insights and updates gleaned from these conferences, offering a glimpse into the latest trends and innovations shaping the future of orthopedic and musculoskeletal care.

• MARKET

Maxx Orthopedics*
SmartTRAK learned at AAOS 2024 that Maxx Medical is going on the offensive to grow its joint replacement business in the US and that the Company plans to launch new hip and knee products in 2024.

Paragon 28*
At AAOS 2024, Paragon 28 noted that its supply chain issues have resolved and does not expect a headwind this year. As a result, Needham believes the company can return to ~20% revenue growth in 2024.

restor3d*
Restor3d reported it currently has 157 active distribution partners calling on ~22,965 orthopedic surgeons and ~18,000 podiatrists. Management noted surgeons will bring difficult cases and from there restor3d can create additional sales opportunities. CG 2024 Musculoskeletal Conference

• REVENUES

BONESUPPORT*
BONESUPPORT highlighted the continued strength of Cerament G in North America with approximate revenues of $17.0MM in Q323 since launching in June 2023. CG 2024 Musculoskeletal Conference

OrthAlign*
At AAOS 2024, SmartTRAK learned that OrthAlign’s 2023 revenue was up +25% to $51MM, led by strong adoption of its Lantern next-generation handheld navigation system and increasing use of the Balance gap balancing feature on Lantern Knee. The company noted +37% growth in the ASC setting.

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

1. Could Reverse Hips Change the Total Hip Game?
   Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement
   
   
2. Three Ortho Robotics Companies to Watch in 2023
   SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.
   
   
3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
   Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.
   
   
   
   

At the 2023 Annual Meeting in monumental Washington DC, the Biologic Association and the American Society of Orthopaedic Surgeons (AAOS) teamed up with American Orthopaedic Society for Sports Medicine (AOSSM) to spotlight the growing interest in and latest advancements of biologics in musculoskeletal medicine. Taking center stage and garnering attention was the idea of “biological healing” and the use of biologics in various conditions and at different points of a continuum of care.

Not surprisingly, the Biological Association focused more on autologous therapies, cell culturing and the next generation of biologics, while the AOSSM meeting explored the current use and growing trends of traditional orthobiologics in orthopedic applications. This article, which is downloadable here, is part one in a two-part series highlighting key takeaways from the Biologic Association meeting, including:

• Biologic Association Key Takeaways
• Rules of Engagement: Regulations and Needed Standards
  • “Same Surgical Procedure Exception” Guidance
  •  Standards for Autologous Orthobiologics
  • Driving Better Patient Outcomes
• Current Use of Autologous Therapies and Next Generation of Biologics
  • Current Practice
  • Next Generation of Biologics
• Notable Investigative Technologies

Although several biologics seem promising to treat musculoskeletal conditions, there is still an uphill battle for widespread use. Current challenges include ...

To download "Biologics in Musculoskeletal Medicine," Part One of the series of articles by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below. Look for Part Two in this series, which will cover key takeaways from AOSSM, highlighting the current use of Orthobiologics and growing trends, in the coming weeks.

The US Orthobiologics (Orthobio) market performed well during the first quarter of 2023 and looks to be on a solid upswing and shining bright with the rebound of elective procedures as drivers to positive momentum. Q123 saw positive growth in all segments of the US Orthobio market, which closed on high notes, with revenue up +8.9% YoY.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Orthobio Market Recap* are:

• Complete Q123 Orthobio Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Orthobio Companies' News, Revenues, Data, Charts and Market Shares
• US Bone Replacement – Springing Back Into Light
  • Growth Factors/Peptides
  • DBM and Synthetics
• US Cartilage Replacement –The Light Continues To Shine Bright
  • Cellular Grafts
  • Osteochondral Grafts
• US Soft Tissue Replacement – Sunny Days Continue
  • Soft Tissue Patches
  • Tendon Allografts
• US Meniscus Replacement – Sun is Shining Back on The Market

Despite continued healthcare staffing shortages and economic uncertainties, the US Bone Replacement experienced high single-digit percentage growth in Q123 as it benefited from increased utilization, especially in ...

Read the entire Q123 US Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

• Top of Mind: M&A and Workforce Reductions
• Macroeconomic Headwinds
• Momentum for Penetrating Larger Addressable Markets
• Companies that are Shifting Strategies
  
  • Anika Therapeutics - Anika has been transforming itself from an osteoarthritis (OA) pain management leader with a huge addressable market to a ...
  • Vericel - US Cartilage Replacement Market leader Vericel continues to shape the market landscape and shift how surgeons are treating ...
  • CONMED - In 2021, CONMED accelerated investments to grow its domestic Orthopedic business, including expanding its ...
• Latest Updates on Pricing and Reimbursement

In summary, this year’s AAOS meeting was energetic, and most of the news and information was positive. SmartTRAK is eager to see the outcomes of the recent acquisitions and activities associated with capturing more market share and ...

To read the complete "The Orthobiologics Buzz at AAOS 2023" article by Kimberly French, GM, Orthobiologics and Regenerative Medicine, just click the button below.

Among the many topics covered in detail in our comprehensive Q422/FY22 OrthoBio Recap* are:

• Complete Q422 Trauma Market Overview and Highlights
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• US Bone Replacement
  • Good Momentum as Spine Rebounds and Products Launch
• US Cartilage Replacement
  • Procedure Volumes Stabilizing
• US Soft Tissue Replacement
  
  • Winter Months More Like a Sunny Day Rose Parade
• US Meniscus Replacement 
  • Growth Dampened by a Non-Blooming Group of Small Players

In addition to the previously mentioned market growth drivers, and as SmartTRAK highlighted in its latest trends article, “What Lies Ahead for Orthobiologics in 2023 and Beyond”,* other contributing factors of growth in 2022 and indicators of future growth in the US Orthobio market, included a tremendous level of M&As, strategic alliances and investments in new technologies. Overall, the US Orthobio market performed above expectations and ...

Read the entire Q422 Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares.*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

The interest and demand for regenerative medicine for various conditions and injuries have increased exponentially over the last decade. From January 1, 1990 to December 31, 2012, google searches for regenerative medicine totaled 21,600,000. With increased publicity about stem cells and advancements in cell and gene therapies, biomaterials and tissue engineering, google searches increased nearly ten-fold to 212,000,000 from 1/1/13 to 2/27/23.

• PRP Trends and the Impacts to 2023 and Beyond
  
  • Headwinds in 2023
  • Trends in PRP Clinical Trials
  • Anticipated 2023 US PRP Market Share Standings
• Adipose Trends and the Impacts to 2023 and Beyond
  • Adipose tissue therapy gaining interest in the field of sports medicine
  • Patient demand for minimally-invasive solutions
  • Adipose-derived cell therapies for OA and Degenerative Disc Disease
    

So is regenerative medicine the way of the future? Time will tell, however, SmartTRAK feels that demand and interest by multiple stakeholders, along with recent trends, medical and legal advancements and investments is tipping the scale to ...

To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

• Synthetic Matrices Poised for Slow Down
• Alternatives to Synthetic Matrices Gaining Favor
  • Xenograft Matrices
  • Resorbable Meshes
  • Reinforced Xenograft Matrices
• Expert Analysis and Conclusions

Market Dynamics, Industry Moves and Technology Advancements 

In 2022, the Orthobiologics Market encountered both ups and downs. Though companies are still reporting year-end results, SmartTRAK feels the Orthobiologics Market finished on a high note. The 2022 challenges, such as staffing shortages at healthcare facilities, supply chain constraints and inflation, may cause headwind in 2023, stifling some growth.

Nevertheless, SmartTRAK anticipates the potential downsides will be offset by elective procedures returning to pre-COVID levels, along with progressive, transitional initiatives by select market players that have the potential to reshape certain orthobiologics segment landscapes.

Among the many topics covered in this Market Outlook article are:

• Reshaping the Competitive Landscape
• Shifts in the US Bone Replacement Market
• Advancements in Osteobiologics
• Shifts in the US Sports Medicine Market